|
Douglas Lind is a Managing Partner of Accendx Management, LLC. He was senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. Previously, he was Managing Director of Lind & Co., a Boston-based biotechnology investment research firm serving institutional clients, which he founded in 1991. He is a former Tufts University Clinical Fellow in Medicine and a past member of the American Medical Association Council on Ethical and Judicial Affairs. During his tenure on the Council, he worked extensively on problems of resource allocation in health care. He has served on numerous national health policy bodies, including the Health Policy Agenda for the American People and the American Medical Association Task Force on Physician Manpower. Dr. Lind is a graduate of the University of Iowa College of Medicine, 1987. From 1990 to 1992, he was a practicing physician in Brookline, Massachusetts. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed his residency in Internal Medicine. | 